Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Vtv Therapeutics

Evaluate

Thumbnail
March 01, 2023

Reata gets a new lease of life

Thumbnail
December 17, 2020

Novo takes the plunge in Alzheimer’s

Novo Nordisk is pushing Rybelsus into a pivotal Alzheimer’s trial despite the failure of the Elad study.

Article image
Vantage logo
February 11, 2020

VTV celebrates a double positive

Yesterday’s clinical study success has underlined VTV's status as a small-cap bet on Alzheibetes.

Article image
Vantage logo
November 26, 2019

Cymabay is out, but for Genfit the band plays on

A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?

Article image
Vantage logo
September 24, 2019

Does amount matter when it comes to a biotech IPO?

Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.

Article image
Vantage logo
June 06, 2019

VTV’s diabetes reinvention gains some ground

After crashing on a late-stage Alzheimer’s failure last year VTV Therapeutics has taken a small step forward in type 1 diabetes.

Vantage logo
April 16, 2018

Interview – Probiodrug hopes to avoid Alzheimer’s amyloid abyss

Vantage logo
April 10, 2018

VTV pivots to diabetes after Alzheimer’s flop

Vantage logo
February 05, 2018

Interview – VTV aims to make novel Alzheimer’s target all the Rage

Vantage logo
December 15, 2016

Eucrisa thumbs up validates Pfizer’s takeover strategy – partly

Vantage logo
October 07, 2016

Upcoming events – Roche’s Avastin heir and vTv’s oral GLP-1

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up